31 results about "Dextromethorphan" patented technology

The invention relates to a hybridoma cell strain capable of secreting dextromethorphan monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain disclosed by the invention has good sensitivity and specificity on dextromethorphan, wherein the IC50 value on the dextromethorphan is 0.162 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of dextromethorphan, such as fentanyl, thilazine, papaverine, morphine and medetomidine, and has good specificity, so that the dextromethorphan with low concentration can be accurately detected.

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and / or to enhance dextromethorphan plasma levels.

The present application provides a detection method and quality control method for related substances in dextromethorphan oral solution, which comprises the following steps: dissolving dextromethorphan oral solution in a solvent to obtain a test solution; and performing high performance liquid chromatography detection on the test solution; the mobile phase used in the high performance liquid chromatography detection comprises mobile phase A and mobile phase B, the mobile phase A comprises a phosphate solution, the mobile phase B comprises acetonitrile, and the concentration of the phosphate solution is 0.1 mM-10 mM. The detection method has good linear relationship between dextromethorphan and related substances, good accuracy and sensitivity, strong specificity, high stability, good separation degree and good reproducibility, and is suitable for wide application.

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

The invention relates to the technical field of organic synthesis, in particular to a refining method of a crude product of dextroborneol, which comprises the following steps: sequentially carrying out a rearrangement reaction, an esterification reaction, a salt forming reaction, an alkaline hydrolysis reaction and post-treatment refining on the crude product of dextroborneol in the presence of a solvent and a catalyst on the basis of a reaction product to obtain a refined product of dextroborneol, in the refined dextroborneol product, the content of dextroborneol is greater than or equal to 98.0%, the content of L-borneol is less than or equal to 1.0%, the content of isoborneol is less than or equal to 0.15%, the content of natural camphor is less than or equal to 0.15%, and the content of other impurities is less than or equal to 0.10%. The method has the advantages that the isoborneol structure can be selectively destroyed under mild conditions, impurities are effectively removed through the esterification-salification-alkaline hydrolysis three-step reaction, and the purity and yield of dextroborneol are remarkably improved.

This invention provides an imine reductase mutant, its preparation method, and its application in the catalytic preparation of dextromethorphan intermediates. The imine reductase mutant is an imine reductase with an amino acid mutation, comprising the amino acid sequence shown in SEQ ID NO:1. The amino acid mutation type includes any one or a combination of at least two of I122T, D212A, or G228R. By introducing a mutation into the imine reductase, this invention significantly improves the enzyme's activity and stereoselectivity, enabling the high-yield synthesis of the dextromethorphan intermediate (S)-1-(4-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline under mild conditions, greatly reducing production costs and making it suitable for industrial production.

An object of the present invention to provide a clozapine-induced sialorrhea alleviator. The clozapine-induced sialorrhea alleviator of the present invention contains as an active ingredient dextromethorphan, a compound having an antagonistic action on an NMDA-type glutamate receptor, or a compound having an agonistic action on a sigma-1 receptor.

The invention discloses solid particles of edaravone and dextroborneol prepared by a wet granulation process and a solid oral quick-release preparation prepared from the solid particles. The solid particles comprise edaravone, dextroborneol, polyethylene glycol and other pharmaceutic adjuvants. According to the present invention, the dextroborneol and the polyethylene glycol are co-dissolved in the absolute ethyl alcohol, and the wet granulation is performed with the edaravone and the pharmaceutical excipients, such that the process feasibility is significantly improved, and the particles with different particle sizes can be prepared according to the absolute ethyl alcohol use amount so as to prepare the oral quick-release tablets with different dosage forms, the dissolving-out speed of the prepared solid particle dextroborneol is obviously improved, and the stability of edaravone is also improved at the same time.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention relates to solid compositions and methods of manufacture. The present invention addresses the problem of providing a solid composition which contains at least one component selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof, and another component, and in which changes in properties are suppressed. [Solution] A solid composition containing the following components: (A) at least one substance selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof; (B) fructose; and (C) one or more components selected from the group consisting of: (C-1) vitamin B1 and vitamin C; (C-2) Chinese herbaceous peony, liquorice and valerian; (C-3) bromhexine, ambroxol, tepiperidine, salts thereof, and hydrates thereof; (C-4) clomastine, salts thereof, and hydrates thereof; and (C-5) dextromethorphan, salts thereof, and hydrates thereof.

The invention belongs to the technical field of pharmaceutical co-crystals, and particularly relates to a synthetic method and application of an amantadine-butylphthalide co-crystal. Butylphthalide reacts to obtain butylphthalide salt or butylphenyltitanic acid, the butylphthalide salt or butylphenyltitanic acid reacts with different substituted amantadine or hydrochloride thereof to synthesize the pharmaceutical co-crystal, and the co-crystal structure can adjust the crystal lattice energy of the pharmaceutical, improve the solubility of the pharmaceutical in water or physiological media, promote the rapid dissolution and absorption of the pharmaceutical in vivo, improve the bioavailability and improve the bioavailability of the pharmaceutical. According to the eutecticum, the problem of solubility of butylphthalide is solved, the formed eutecticum shows certain neuroprotective activity, the biological activity of the eutecticum is remarkably superior to that of a monomer drug, the clinical medication dosage can be reduced while the same treatment effect is achieved, and the eutecticum has certain scientific research value and industrial popularization significance.

The present invention provides a method of treating depression disease in a treatment resistant patient comprising administering to a mucosal membrane of a patient an effective amount of a pharmaceutically acceptable composition comprising an effective amount of ketamine or dextromethorphan, wherein the mucosal administration of the ketamine or dextromethorphan containing composition allows for the mucosal absorption of the composition eliminating the digestive tract of the patient for effecting a rapid acting antidepressant treatment of the treatment resistant patient. This method includes administering the composition to a patient's mucosal membrane of a respiratory tract, a genitourinary tract, an oral tract, or rectal tract of the patient. A pharmaceutically acceptable composition comprising ketamine or dextromethorphan and a vehicle is disclosed. A biomarker for identifying a depressive disease is set forth.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention belongs to the technical field of sensors, and particularly relates to a surface plasmon resonance sensor based on a molecularly imprinted polymer and a preparation method of the surface plasmon resonance sensor. The preparation method comprises the following steps: preparing an SPR chip with an Au / Cr / cover glass structure by adopting a magnetron sputtering method; then polydopamine is electrically polymerized on the surface to form a PDA / Au / Cr / cover glass structure; the preparation method comprises the following steps: preparing a dextromethorphan molecularly imprinted polymer (DXM-MIP) by taking p-mercaptophenol as a functional monomer and dextromethorphan as a template molecule through an electropolymerization method to form a DXM-MIP / PDA / Au / Cr / cover glass structure, and finally eluting the template molecule to obtain the surface plasmon resonance sensor (DXM-MIP / SPR sensor) based on the molecularly imprinted polymer. The DXM-MIP / SPR sensor is suitable for high-selectivity, wide-range, efficient and low-cost detection of dextromethorphan, and is especially suitable for qualitative and quantitative detection of dextromethorphan in drugs.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The present disclosure relates to use of a pharmaceutical composition. Specifically, the pharmaceutical composition provided by the present disclosure is used for treating inflammatory depression, wherein the pharmaceutical composition comprises: (i) dextromethorphan or a salt of dextromethorphan and (ii) celecoxib or a salt of celecoxib. The pharmaceutical composition of the present disclosure is directed to inflammatory depression (especially inflammatory treatment-resistant depression and anhedonia depression).

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

To provide a solid composition containing ibuprofen with improved dissolution properties. [Solution] A solid composition comprising (A) ibuprofen and (B) at least one selected from the group consisting of noscapine, dextromethorphan, and salts thereof (excluding (i) a solid composition that does not contain dextromethorphan or a salt thereof and in which ibuprofen and noscapine or a salt thereof exist as different granules, and (ii) a solid composition that does not contain noscapine or a salt thereof and in which ibuprofen, dextromethorphan or a salt thereof, a polymer that forms a hydrogel, and an organic acid or an acidic amino acid).

Disclosed herein is a method of treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and are CYP2D6 poor metabolizers.

This disclosure provides a pharmaceutical composition, a kit, and its use. The pharmaceutical composition provided in this disclosure comprises deuterated dextromethorphan or a salt thereof and celecoxib.

Dosage forms, drug delivery systems, and methods related to the sustained release of dextromethorphan or enhanced therapeutic effects are disclosed. Typically, bupropion or a related compound is administered orally to a human being treated with or who is being treated with dextromethorphan.

The application belongs to the field of medicine, and specifically provides a method for preparing an important intermediate compound N-(2-(cyclohex-1-en-1-yl)ethyl)-2-p-methoxyphenylacetamide of dextromethorphan. The application uses 2-(1-cyclohexenyl)ethylamine and p-methoxyphenylacetic acid as raw materials, selects N,N-carbonyldiimidazole as a condensation reagent, optimizes the reaction conditions, reduces the reaction temperature, shortens the reaction time, and has the advantages of simple post-treatment, high product yield and purity, low cost, and being more beneficial to industrial production.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

To provide a solid composition containing ibuprofen and tranexamic acid with improved dissolution persistence. [Solution] A solid composition comprising (A) ibuprofen, (B) at least one selected from the group consisting of dextromethorphan and its salts, and (C) tranexamic acid.

This invention belongs to the field of sensor technology, specifically relating to a surface plasmon resonance sensor based on molecularly imprinted polymers and its fabrication method. The invention employs magnetron sputtering to fabricate an Au / Cr / cover glass structure SPR chip; then, polydopamine is electropolymerized on the surface to form a PDA / Au / Cr / cover glass structure; next, using p-mercaptophenol as a functional monomer and dextromethorphan as a template molecule, a dextromethorphan molecularly imprinted polymer (DXM-MIP) is prepared by electropolymerization, forming a DXM-MIP / PDA / Au / Cr / cover glass structure. Finally, the template molecule is eluted to obtain a surface plasmon resonance sensor based on molecularly imprinted polymers (DXM-MIP / SPR sensor). The DXM-MIP / SPR sensor is suitable for the highly selective, wide-range, efficient, and low-cost detection of dextromethorphan, especially for the qualitative and quantitative detection of dextromethorphan in pharmaceuticals.

To provide a solid composition containing at least one selected from the group consisting of loxoprofen, a salt thereof and a hydrate thereof, and other components, and having suppressed property change.SOLUTION: (A) at least one member selected from the group consisting of loxoprofen and salts and hydrates thereof, (B) fructose, and (C) one or more members selected from the group consisting of (C- 1) vitamin B1 and vitamin C, (C- 2) peony root, licorice, and valerian, (C- 3) bromhexine, ambroxol, tipepidine and salts and hydrates thereof, (C- 4) clemastine and salts and hydrates thereof, and (C- 5) dextromethorphan and salts and hydrates thereof; A solid composition comprising: SELECTED DRAWING: None

The invention relates to a solid composition, an agent for improving dissolution of ibuprofen, and a method for improving dissolution of ibuprofen. The present invention addresses the problem of providing a solid composition containing ibuprofen having improved dissolution properties. [Solution] A solid composition which contains (A) ibuprofen and (B) at least one substance selected from the group consisting of noscabine, dextromethorphan, and salts thereof, and which does not contain: (i) a solid composition which does not contain dextromethorphan or a salt thereof and in which ibuprofen and noscabine or a salt thereof are present as different granulated materials; and (ii) a solid composition which does not contain noscabine or a salt thereof and comprises ibuprofen, dextromethorphan or a salt thereof, a hydrogel-forming polymer, and an organic acid or acidic amino acid.